| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 546.000 +25.46% on 01/06/26 | | 685.000 unch on 01/20/26 | +87.000 (+14.55%) since 12/19/25 |
| 3-Month | 356.000 +92.42% on 12/05/25 | | 1,215.000 -43.62% on 10/29/25 | -315.000 (-31.50%) since 10/20/25 |
| 52-Week | 124.000 +452.42% on 07/15/25 | | 1,800.000 -61.94% on 09/17/25 | +335.000 (+95.71%) since 01/20/25 |
LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase...
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces...
Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML
LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI...
Recruitment of Second Patient for HG-CT-1 Clinical Trial
Institutional backing of £709,200 for continuing Phase 1 Clinical Trials
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI...
LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares")...
| 3rd Resistance Point | 678.000 |
| 2nd Resistance Point | 657.000 |
| 1st Resistance Point | 642.000 |
| Last Price | 688.000 |
| 1st Support Level | 606.000 |
| 2nd Support Level | 585.000 |
| 3rd Support Level | 570.000 |
| 52-Week High | 1,800.000 |
| Fibonacci 61.8% | 1,159.768 |
| Fibonacci 50% | 962.000 |
| Fibonacci 38.2% | 764.232 |
| Last Price | 688.000 |
| 52-Week Low | 124.000 |